Certificate of Analysis
DOC QC-COA-0409-FOX-10-126-26 · REV 1Triple-tested · Raw material is tested before vialing, the finished vial is tested for sterility, and every lot is released on an independent laboratory certificate.
Test results
| Test | Method | Specification | Result | Verdict |
|---|---|---|---|---|
| Identity | LC-MS | Observed mass conforms to theoretical | Conforms · LC-MS 1073.2[M+5H], | PASS |
| Purity | HPLC-UV | ≥ 95% | 99.40% | PASS |
| Net content | LC-MS · gravimetric | Report | 10.2 mg | PASS |
Source document
AxisPharm, LLC · Independent analytical laboratory. Reference 13May2026-03 · sample received May 8, 2026 · reported May 13, 2026.
The results above are transcribed from the laboratory's certificate for this lot. Atlas RND hosts a copy of that document; the original is the authority, so open it to confirm every figure.
Conclusion. Lot FOX-10-126-26 of FOXO4-DRI 10 mg meets the release specification for every test listed above and is approved for distribution for laboratory research use only. Testing performed by AxisPharm, LLC, an independent analytical laboratory, independent of Atlas RND.
www.atlasrnd.co/coa/fox-10-126-26
LAB REFERENCE 13May2026-03